Haoyuan Pharmaceutical (688131.SH) subsidiary Yaoyuan Qidong passes the US FDA audit.

Zhitong Finance APP news, Haoyuan Pharmaceutical (688131.SH) announced that its wholly-owned subsidiary, Yaoyuan Biotechnology (Qidong) Co., Ltd. (referred to as Yaoyuan Qidong), underwent a pre-approval inspection by the U.S. Food and Drug Administration (referred to as FDA) from June 22 to June 26, 2026. Recently, the company received the on-site inspection report issued by the FDA, forwarded by Yaoyuan Qidong, which indicates that Yaoyuan Qidong passed this inspection with zero deficiencies. This inspection marks the first time the companys formulation production base has been inspected by the FDA and successfully passed, providing a solid assurance for the company's continued expansion into the U.S. market.